{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-090482","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2026-08-17T11:17:57+00:00","discovered_at":"2026-08-17T11:20:00.548926+00:00","generated_at":"2026-08-17T11:20:29.364141+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Adial reports Q2 net loss of $52M; closes Azora acquisition and $32M financing","bullets":["Net loss of $52.0M ($11.25/share) vs $2.0M loss ($4.61/share) in Q2 2025; includes $46.2M non-cash IPR&D charge.","Completed acquisition of Azora Therapeutics, adding AT177, an oral colon-targeted AhR agonist for ulcerative colitis; IND planned for H1 2027.","Closed initial $32M tranche (incl. $5.5M note conversion) of up to $64M private placement; cash $28.7M at June 30 vs $4.6M at March 31.","G&A expenses rose to $5.4M from $1.2M YoY on merger costs and severance; R&D fell to $440K from $732K.","Cash runway into H2 2027; stockholders' deficit of $38.4M with $38.5M Series A preferred pending conversion approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-090482","json":"https://secwatch.observer/filing/0001213900-26-090482.json","markdown":"https://secwatch.observer/filing/0001213900-26-090482.md","text":"https://secwatch.observer/filing/0001213900-26-090482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026090482/0001213900-26-090482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026090482/ea0301966-8k_adial.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-17T11:20:29.364141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}